A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia Journal Article


Authors: Kheradpour, A.; Berman, E.; Göker, E.; Lin, J. T.; Tong, W. P.; Bertino, J. R.
Article Title: A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia
Abstract: Trimetrexate, a second-generation folate antagonist, is a potent inhibitor of dihydrofolate reductase with a broader spectrum of activity and different mechanism of entry and intracellular accumulation than methotrexate. Six patients with refractory or relapsed acute leukemia were treated with a 5-day continuous infusion of trimetrexate of 8 mg/m2 /day after an initial loading dose of 4 mg/m2 to achieve a target plasma concentration of 0.2-0.5 μM. In 4 patients with peripheral blasts at study entry, transient decrease or disappearance of blasts was observed, although no decrease of bone marrow blasts occurred. Mucositis was dose-limiting and severe in 4 patients. Neutrophil and platelet nadirs occurred on day 5-12 postinfusion. Because of dose-limiting mucositis, this dose schedule of trimetrexate is not recommended for further studies in refractory acute leukemia. However, other dose schedules (24- to 72-hr infusions) and its use as a modulating agent with thiopurines or leucovorin in patients that are resistant to methotrexate should be explored. © 1995 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
Keywords: adult; clinical article; aged; clinical trial; fatigue; phase 2 clinical trial; leukopenia; mucosa inflammation; nausea; thrombocytopenia; acute leukemia; folinic acid; drug blood level; infusions, intravenous; intravenous drug administration; mercaptopurine; trimetrexate; leukemia, myelocytic, acute; leukemia, lymphocytic, acute; human; male; female; priority journal; article; support, non-u.s. gov't
Journal Title: Cancer Investigation
Volume: 13
Issue: 1
ISSN: 0735-7907
Publisher: Informa Healthcare  
Date Published: 1995-01-01
Start Page: 36
End Page: 40
Language: English
DOI: 10.3109/07357909509024893
PUBMED: 7834472
PROVIDER: scopus
DOI/URL:
Notes: Article -- Export Date: 28 August 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. William Ping-Yiu Tong
    158 Tong
  2. Joseph Bertino
    363 Bertino
  3. Ellin Berman
    173 Berman
  4. James T. Lin
    14 Lin